Tahir Latif
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma (NCT03688451) | Tahir Latif | 2018-10-29 |
Track Tahir Latif automatically
Every clearance here is in the API, with alerts when new ones post.